# Regeneron Pharmaceuticals

**Source:** https://geo.sig.ai/brands/regeneron-pharmaceuticals  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** regeneron-pharmaceuticals.com  
**Last Updated:** 2026-04-14

## Summary

Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.

## Company Overview

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.

Regeneron's commercial portfolio is led by Dupixent (dupilumab) — a monoclonal antibody targeting IL-4 and IL-13 for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other allergic/inflammatory conditions. Dupixent has become one of the fastest-growing drugs in pharmaceutical history, with global sales exceeding $14B annually and ongoing label expansion into new indications. Other key products include Eylea (aflibercept) for macular degeneration and diabetic eye disease, Praluent (alirocumab) for high cholesterol, Kevzara (sarilumab) for rheumatoid arthritis, and Libtayo (cemiplimab) for certain skin and lung cancers.

Regeneron trades on NASDAQ (REGN) with a market cap of approximately $55–70B. The company has one of the most productive R&D organizations in biotech — its VelociSuite technology enables rapid antibody and bispecific generation. In 2024, the FDA approved a Dupixent biosimilar competition timeline, creating a long-term revenue headwind that Regeneron is offsetting through new indications and pipeline development including Dupixent for COPD, oncology bispecifics, and obesity programs.

## Frequently Asked Questions

### What is Regeneron's annual revenue?
Regeneron reported $13.9B in revenue for FY2024, up approximately 7% year-over-year, driven primarily by continued Dupixent growth and stable Eylea sales.

### What is Dupixent?
Dupixent (dupilumab) is Regeneron's blockbuster biologic antibody that treats multiple allergic and inflammatory diseases: atopic dermatitis (eczema), asthma, chronic sinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Global sales exceed $14B annually.

### What is Regeneron's stock ticker?
Regeneron Pharmaceuticals trades on NASDAQ under ticker REGN. It is a component of the S&P 500 and NASDAQ-100.

### Who developed Dupixent?
Dupixent was co-developed by Regeneron and Sanofi. Sanofi and Regeneron share profits from global Dupixent sales under a longstanding collaboration agreement.

### Who are Regeneron's competitors?
Regeneron competes with AstraZeneca/AZ (Fasenra for asthma), Eli Lilly (Lebrikizumab for atopic dermatitis), and Abbvie/Johnson & Johnson (Rinvoq, Tremfya) in immunology. In oncology, it competes with Merck (Keytruda), Bristol-Myers (Opdivo), and Roche.

### What is Regeneron's pipeline beyond Dupixent?
Regeneron's pipeline includes Dupixent for new indications (COPD approved 2024, additional autoimmune diseases in trials), Kevzara (IL-6 for RA), Praluent (PCSK9 for cholesterol), Libtayo (PD-1 checkpoint inhibitor for cancers), and a growing oncology antibody portfolio. Regeneron Genetics Center (RGC) supports discovery with genomic data from 2+ million participants, identifying novel drug targets for future programs.

### What is the Regeneron Genetics Center and why does it matter?
The Regeneron Genetics Center (RGC) is one of the world's largest human genetics programs, having sequenced the exomes of over 2 million individuals in partnership with large health systems including Geisinger and UK Biobank. By linking genetic variants to health outcomes across millions of patients, RGC identifies which gene targets are most likely to produce safe and effective drugs — dramatically improving Regeneron's clinical success rates compared to the industry average.

### How dependent is Regeneron on Dupixent?
Dupixent accounted for approximately $14B of Regeneron's $13.9B in 2024 revenue — meaning Dupixent alone (shared with Sanofi) generates more than Regeneron's total reported revenue due to accounting for collaboration structure. This high concentration is a risk factor, but Dupixent continues expanding into new indications and geographies. Regeneron's growing oncology portfolio (Libtayo) and genetic medicine pipeline are intended to diversify revenue over the coming decade.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*